Compare VNO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNO | HALO |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | 3145 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 8.8B |
| IPO Year | N/A | 2001 |
| Metric | VNO | HALO |
|---|---|---|
| Price | $30.66 | $67.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $33.00 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $5.42 | $12.56 |
| P/E Ratio | ★ $7.08 | $56.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.57 | $51.06 |
| 52 Week High | $43.37 | $82.22 |
| Indicator | VNO | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 52.10 |
| Support Level | $28.48 | $62.53 |
| Resistance Level | $32.73 | $70.93 |
| Average True Range (ATR) | 0.92 | 2.67 |
| MACD | -0.06 | 0.43 |
| Stochastic Oscillator | 46.40 | 42.57 |
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.